To ensure that GO complexation with BTZ did not inhibit BTZ function, we treated U87‐MG and GL261 glioma cells with increasing doses of GO:BTZ (based on BTZ molarity) under the same conditions as previously described. The gene discussed is CASC3; the disease is central nervous system cancer.